Neuren Pharmaceuticals Limited announced that Dr. Richard Treagus has joined its Board. Dr. Treagus will also
become the Board's Executive Chairman. He will be engaged in an executive capacity to review company's business, financial and commercial strategy. He will work with Larry Glass, the company's CEO and Managing Director, in executing the company's business plan to realize the company's value for shareholders. Richard has an extensive global network and a strong track record of being able to deliver exceptional outcomes and shareholder returns in a complex business environment. Combining his medical training with a business qualification, Richard has over 20 years' strategic and operational experience in all aspects of the international pharmaceutical industry. He has held a variety of senior executive roles with pharmaceutical organizations in South Africa and Australia, and over the years has successfully built numerous business partnerships across the US, Europe and Asia. Richard's most recent role was as Chief Executive of Acrux. The Board expects that Richard will be able to use his experience, his extensive business network and his knowledge of the Australian capital markets in particular, to help realize Neuren's full potential and the market's appreciation of it. Dr. Robin Congreve, who has led Neuren since its listing on the ASX in 2004 will remain on the Board.